{"nctId":"NCT01950299","briefTitle":"Interleukin-1 (IL-1) Blockade in Acute Myocardial Infarction (VCU-ART3)","startDateStruct":{"date":"2014-07-01","type":"ACTUAL"},"conditions":["Acute Myocardial Infarction"],"count":99,"armGroups":[{"label":"Anakinra (standard dose)","type":"EXPERIMENTAL","interventionNames":["Drug: Anakinra 100 mg","Drug: Placebo"]},{"label":"Anakinra (high dose)","type":"EXPERIMENTAL","interventionNames":["Drug: Anakinra 100 mg"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"Anakinra 100 mg","otherNames":["Kineret"]},{"name":"Anakinra 100 mg","otherNames":["Kineret"]},{"name":"Placebo","otherNames":["Placebo injections twice daily"]}],"eligibilityModule":{"eligibilityCriteria":"INCLUSION CRITERIA:\n\nIn order to be eligible for this study, patients must meet ALL the 3 Inclusion criteria and NONE of the Exclusion criteria.\n\n1. Acute STEMI defined as chest pain (or equivalent) with an onset within 12 hours and ECG evidence of ST segment elevation (\\>1 mm) in 2 or more anatomically contiguous leads that is new or presumably new\n2. Planned or completed coronary angiogram for potential intervention\n3. Age\\>21\n\nEXCLUSION CRITERIA:\n\n* Inability to give informed consent\n* Pregnancy\n* Preexisting congestive heart failure (American Heart Association/American College of Cardiology class C-D, New York Heart Association III-IV)\n* Preexisting severe left ventricular dysfunction (EF\\<20%)\n* Preexisting severe valvular heart disease\n* Active infections (acute or chronic) - excluding Hepatitis C Virus (HCV)+ with undetectable RNA\n* Recent (\\<14 days) or active use of anti-inflammatory drugs (not including non-steroidal anti-inflammatory drugs \\[NSAIDs\\] or corticosteroids used for IV dye allergy only)\n* Chronic inflammatory disease (including but not limited to rheumatoid arthritis, systemic lupus erythematosus)\n* Active malignancy - excluding carcinoma in situ \\[any organ\\] and non-melanoma skin cancer\n* Anticipated need for cardiac surgery\n* Neutropenia (absolute neutrophil count\\<1,800/mm3)","healthyVolunteers":false,"sex":"ALL","minimumAge":"21 Years","maximumAge":"99 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Acute Phase Response (CRP Levels)","description":"Comparison of area-under-the-curve for CRP up to day 14","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"60.03","spread":null},{"groupId":"OG001","value":"86.35","spread":null},{"groupId":"OG002","value":"213.75","spread":null}]}]}]},{"type":"SECONDARY","title":"Left Ventricular End-systolic Volume","description":"Placebo corrected interval change in left ventricular end-systolic volume over 12 months","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"4","spread":null},{"groupId":"OG002","value":"-4","spread":null}]}]}]},{"type":"SECONDARY","title":"Left Ventricular Ejection Fraction","description":"Placebo-corrected interval changes in left ventricular ejection fraction over 12 months","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"5","spread":null},{"groupId":"OG002","value":"3","spread":null}]}]}]},{"type":"SECONDARY","title":"Heart Failure","description":"New onset of heart failure symptoms (NYHA II-IV)","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"3","spread":null},{"groupId":"OG002","value":"9","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":6,"n":33},"commonTop":["Injection Site Reaction"]}}}